Business
Director Dealings
Director Dealings.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 1835P NetScientific PLC 30 September 2013 \n \n\n\n\n\n\n\n\n\n30 September 2013\n\n\n\n\n \nNetScientific plc \n(\"NetScientific\" or the \"Group\")\n \nDirector Dealings\n \nNetScientific, the healthcare medical technology company, announces that on 27 September 2013 it received notification that, on 27 September 2013, Barry Wilson, Non Executive Director of the Group, purchased 6,150 ordinary shares of 5p each in the capital of the Group (\"Ordinary Shares\") at a price of 161p per share.\n \nFollowing this transaction, Barry Wilson will hold 15,525 Ordinary Shares representing approximately 0.04% of the issued ordinary share capital of the Group.\n \n- Ends -\n \n \nFor further information, please contact:\n \n\n\n\n\nNetScientific plc\nFarad Azima, Chief Executive Officer\n\n\nTel: +44 (0) 20 3590 8877\n\n\n\n\nLiberum Capital (Nomad & Broker)\nChris Bowman / Christopher Britton / Thomas Bective\n\n\nTel: +44 (0) 20 3100 2000\n\n\n\n\nBell Pottinger\nDaniel de Belder\n\n\nTel: +44 (0) 20 7861 3232\n\n\n\n\n \nCompany website:www.netscientific.net\n \n \nAbout NetScientific\n \nNetScientific is a healthcare medical technology company that identifies, develops and commercialises research and technologies originating from leading universities, teaching hospitals and research institutes globally, particularly in the United Kingdom and the United States. The Group is primarily focused on identifying and developing research and technologies for use in five chronic disease areas within the healthcare diagnostics sector: (i) cardiovascular; (ii) liver; (iii) cancer; (iv) metabolic; and (v) digital health.\n \nThe Group's core strategy is to fund and develop translational technologies that offer transformative benefits to peoples' lives and society through improved diagnosis, monitoring and treatment of chronic disease. Chronic diseases account for more than 70 per cent. of healthcare expenses in each of the United States and the United Kingdom, according to the Centers for Disease Control and Prevention and the UK Department of Health. Accordingly, reducing the cost of diagnosing, monitoring and treating chronic disease has become one of the key challenges to the global healthcare sector. Consequently, the...